BREAKING NEWS: Stent Panel Recommends Warnings on Devices

Article

GAITHERSBURG, Md. -- The FDA's drug-eluting stent safety panel recommended today that the labels of Cypher (sirolimus-eluting) and Taxus (paclitaxel-eluting) stents be changed to include a warning that off-label use of the devices may carry an increased risk of stent thrombosis, myocardial infarction, and death. The panel also called for the label to carry a recommendation for 12-months of dual antiplatelet therapy with aspirin and Plavix (clopidogrel) when drug-eluting stents are used off-label.

GAITHERSBURG, Md., Dec. 8 -- The FDA's drug-eluting stent safety panel recommended today that the labels of Cypher (sirolimus-eluting) and Taxus (paclitaxel-eluting) stents be changed to include a warning that off-label use of the devices may carry an increased risk of stent thrombosis, myocardial infarction, and death. The panel also called for the label to carry a recommendation for 12-months of dual antiplatelet therapy with aspirin and Plavix (clopidogrel) when drug-eluting stents are used off-label.

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients

Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients

Sydney Jennings
April 25th 2025
Article

In a real-world study of patients with Crohn disease, upadacitinib achieved 52.1% clinical remission at 12 weeks and 42.7% endoscopic remission at 6 months, with no new safety concerns reported.

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Linda Stein Gold, MD;Sydney Jennings
March 9th 2025
Podcast

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Postpartum Hormonal Contraceptive Use Linked to Increased Risk of Depression / image credit Copenhagen University Hospital

Postpartum Hormonal Contraceptive Use Linked to Increased Risk of Depression

Grace Halsey
April 25th 2025
Article

The increased risk of depression when oral contraceptives were started following childbirth was "instantaneous," researchers wrote, and was ~50% greater than nonuse.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose

Sydney Jennings
April 25th 2025
Article

Your daily dose of the clinical news you may have missed.

New-Onset Type 2 Diabetes Tied to Higher Risk of Specific Obesity-Related Cancers

New-Onset Type 2 Diabetes Tied to Higher Risk of Specific Obesity-Related Cancers

Sydney Jennings
April 24th 2025
Article

New data to be presented at ECO 2025 shows new-onset T2D is linked to increased risk of liver, pancreatic, and bowel cancers, but not endometrial or post-menopausal breast cancer.

© 2025 MJH Life Sciences

All rights reserved.